Dr. Linlin Li 李琳琳
Chief Physician
Department of Medical Oncology, Liaoning Cancer Hospital & Institute, Shenyang
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy, biological therapy, and targeted therapy for lung cancer, lymphoma, breast cancer, colorectal cancer, gastric cancer, and other digestive system tumors.
Dr. Li is a Chief Physician at Liaoning Cancer Hospital & Institute. Dr. Li performs intracavitary catheterization for malignant pleural and ascites fluid and uses combined chemotherapy, immunotherapy, traditional Chinese medicine, and targeted therapy for advanced malignancies. Dr. Li has published academic papers in national core journals and SCI-indexed journals, led one provincial-level research project, and participated in two others.
Professional roles
- Chair, Youth Committee of Tumor Metastasis Professional Committee, Liaoning Anti-Cancer Association
- Standing Committee Member, Tumor Metastasis Professional Committee, Liaoning Anti-Cancer Association
- Member, Geriatric Oncology Professional Committee, Liaoning Life Science Society
- Member, Lymphoma Professional Committee, Liaoning Anti-Cancer Association
Name order: in Chinese the family name comes first (Li Linlin). Papers usually list the name as Linlin Li or Li L.
Selected publications
11 papers on PubMed matched by name and affiliation; 4 as first or senior author since 2016. Most recent first- or senior-author papers:
- Heliyon, 2023 (first author): N-telopeptide as a potential diagnostic and prognostic marker for bone metastasis in human cancers: A meta-analysis. PubMed 37215848
- Int J Oncol, 2023 (first author): [Retracted] Tripartite motif 16 inhibits hepatocellular carcinoma cell migration and invasion. PubMed 36601755
- Biomed Res Int, 2021 (first author): Association between Coalmine Dust and Mortality Risk of Lung Cancer: A Meta-Analysis. PubMed 33763477
- Int J Oncol, 2016 (first author): Tripartite motif 16 inhibits hepatocellular carcinoma cell migration and invasion. PubMed 26892350
- Int J Clin Exp Med, 2015 (first author): Association of 8q23-24 region (8q23.3 loci and 8q24.21 loci) with susceptibility to colorectal cancer: a systematic and updated meta-analysis. PubMed 26885031
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion